Aclarion, Inc. (ACON)
| Market Cap | 8.10M +103.2% |
| Revenue (ttm) | 75,730 +65.6% |
| Net Income | -7.24M |
| EPS | -13.61 |
| Shares Out | 2.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,631 |
| Open | 3.170 |
| Previous Close | 3.150 |
| Day's Range | 3.122 - 3.340 |
| 52-Week Range | 2.340 - 12.030 |
| Beta | 1.19 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+112.77%) |
| Earnings Date | May 15, 2026 |
About ACON
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standa... [Read more]
Financial Performance
In 2025, Aclarion's revenue was $75,730, an increase of 65.62% compared to the previous year's $45,724. Losses were -$7.24 million, 2.66% more than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for ACON stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
Aclarion enters second commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/We...
Aclarion announces $2.5M share repurchase program
Aclarion (ACON) announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company’s outstanding common stock. Aclarion expects to execute the repurchase…
Aclarion granted U.S. patent for AI-driven back pain assessment
Aclarion (ACON) announced the issuance of a U.S. patent covering its machine learning-based platform for analyzing magnetic resonance spectroscopy, or MRS, data. Aclarion’s cloud-based platform, Nocis...
Aclarion Receives Pinnacle Award for AI Innovation
Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) -- Aclarion,...
Aclarion announces commercial agreement with Weill Cornell Medicine
Aclarion (ACON) announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cor...
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The Londo...
Echo Lake calls on Aclarion director David Neal to resign
Ephraim Fields of Echo Lake Capital sent a letter to David Neal, a member of the Board of Directors of Aclarion (ACON). The letter read, in part, “We believe we…
Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc.
Stock has declined 99% since its IPO Believes Neal has repeatedly failed to fulfill his fiduciary responsibility Since 2021 Neal has received $240,000 Board compensation Accepted 20% pay increase in 2...
Aclarion adopts limited duration stockholder rights plan
Aclarion (ACON) announced that its Board of Directors has unanimously adopted a limited duration stockholder rights plan. The Rights Plan is effective immediately and expires in one year. The Rights…
Aclarion’s CEO publishes shareholder letter
Aclarion (ACON)published a shareholder letter from CEO Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026. The letter highlights Aclarion’s “continu...
Aclarion strengthens balance sheet, extends cash runway into 2028
Aclarion (ACON) announced the closing of a $10.4M common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion’s balance sheet, pr...
Aclarion Inc trading halted, volatility trading pause
09:59 EST Aclarion (ACON) Inc trading halted, volatility trading pause
Why Is Aclarion Stock (ACON) Up Today?
Aclarion stock gained on Thursday alongside a corporate update and new guidance.
Aclarion says first patients enrolled at two additional CLARITY trial sites
Aclarion (ACON) announced that Northwestern Medicine and Scripps Health have enrolled their first patients in the company’s pivotal CLARITY trial, advancing enrollment progress in the trial. The compa...
Aclarion announces publication of Nociscan article in pain issue of IJSS
Aclarion (ACON) announced the publication of a featured article Tech Update, sponsored by Aclarion, in the upcoming Special Pain Issue of the International Journal of Spine Surgery, IJSS. “We are…
Aclarion appoints Jason Brosniak as commercial director, Eastern U.S.
Aclarion (ACON) announced the appointment of Jason Brosniak as Commercial Director, Eastern U.S. Jason is a proven commercial leader with more than 20 years of experience accelerating revenue growth a...
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technol...
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion's breakthrough Nociscan solution for chronic low back pain ...
Aclarion Transcript: LD Micro Main Event XIX Investor Conference
Strong financial footing and NASDAQ compliance support rapid growth in a $10B+ market, driven by a patented, AI-powered SaaS diagnostic for chronic back pain. Clinical trials and payer adoption in London and the U.S. are accelerating physician uptake and scan volumes.
Aclarion to Present at the LD Micro Main Event XIX
Presentation on Monday, October 20, 2025 at 12:00 PM PT Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a health...
Aclarion presents on Nociscan technology at LSI Europe ’25
Aclarion (ACON) announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. During the presentation, CEO Brent Ness shared how Aclarion’s flagship platfor...
Aclarion announces first enrollment at pivotal CLARITY trial
Aclarion (ACON) announced that the UHealth – University of Miami Health System and the Miller School of Medicine enrolled its first two patients in the CLARITY – Chronic Low bAck…
Aclarion names Greg Gould as CFO, effective immediately
Aclarion (ACON) announced the appointment of Greg Gould as CFO, effective immediately. Greg brings more than 30 years of public and private company experience with a proven track record of…
Aclarion announces first patient enrolled in Clarity trial
Aclarion (ACON) announced the first patient enrollment in the Clarity trial evaluating Nociscan’s clinical and economic value in spine surgery. The first patient was enrolled at the Texas Back Institu...